The Present and Future
State-of-the-Art Review
Cardiac Fibrosis in Patients With Atrial Fibrillation: Mechanisms and Clinical Implications

https://doi.org/10.1016/j.jacc.2015.06.1313Get rights and content
Under an Elsevier user license
open archive

Abstract

Atrial fibrillation (AF) is associated with structural, electrical, and contractile remodeling of the atria. Development and progression of atrial fibrosis is the hallmark of structural remodeling in AF and is considered the substrate for AF perpetuation. In contrast, experimental and clinical data on the effect of ventricular fibrotic processes in the pathogenesis of AF and its complications are controversial. Ventricular fibrosis seems to contribute to abnormalities in cardiac relaxation and contractility and to the development of heart failure, a common finding in AF. Given that AF and heart failure frequently coexist and that both conditions affect patient prognosis, a better understanding of the mutual effect of fibrosis in AF and heart failure is of particular interest. In this review paper, we provide an overview of the general mechanisms of cardiac fibrosis in AF, differences between fibrotic processes in atria and ventricles, and the clinical and prognostic significance of cardiac fibrosis in AF.

Key Words

cardiac
extracellular matrix
heart failure
myocytes
myofibroblasts

Abbreviations and Acronyms

AF
atrial fibrillation
CHADS2
congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, and stroke/transient ischemic attack
CMR
cardiac magnetic resonance
CTGF
connective tissue growth factor
DE-CMR
delayed gadolinium enhancement cardiac magnetic resonance
ECM
extracellular matrix
HF
heart failure
miR
microribonucleic acid
MMP
matrix metalloproteinase
NADPH
nicotinamide adenine dinucleotide phosphate
PDGF
platelet-derived growth factor
TGF-β1
transforming growth factor beta-1

Cited by (0)

Dr. Dzeshka was supported by a European Heart Rhythm Association Academic Fellowship Programme. Dr. Lip has served as a consultant for Bayer, Astellas, Merck, Sanofi, Bristol-Myers Squibb/Pfizer, Biotronik, Medtronic, Portola, Boehringer Ingelheim, Microlife, and Daiichi-Sankyo; and has been on the speakers bureau for Bayer, Bristol-Myers Squibb/Pfizer, Medtronic, Boehringer Ingelheim, Microlife, and Daiichi-Sankyo. Drs. Snezhitskiy and Shantsila have reported that they have no relationships relevant to the contents of this paper to disclose.

Listen to this manuscript's audio summary by JACC Editor-in-Chief Dr. Valentin Fuster.